OPRM1 and cystic fibrosis: For pediatric patients with CF, aminoglycosides are a critical component of antipseudomonal therapy for the treatment of lung infections (9), but treating such infections is becoming challenging due to intrinsic resistance conferred by MexXY-OprM (16, 17).